A New Multiple Myeloma Indication for Daratumumab and ...

Hyaluronidase-fihj is an enzyme that breaks down hyaluronan, a component of the extracellular matrix. Since the extracellular matrix acts as a barrier between ...

FDA approves daratumumab and hyaluronidase-fihj with bortezomib ...

On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research ...

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard ...

based quadruplet regimen for newly diagnosed multiple myeloma ...

Results from CEPHEUS study highlight DARZALEX FASPRO® quadruplet regimen as a potential standard of care in newly diagnosed patients ...

Johnson & Johnson submits applications in the U.S. and EU seeking ...

If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of ...

FDA Approves Subcutaneous Daratumumab Plus VRd in Multiple ...

The FDA approved Darzalex Faspro plus VRd for induction and consolidation in select patients with newly diagnosed multiple myeloma.

EMA Recommends Extension of Therapeutic Indications for ...

DARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly ...

Subcutaneous daratumumab and hyaluronidase-fihj in newly ...

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for ...

Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab ...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone ...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Outperforms VRd Alone for Multiple Myeloma ... (SAN DIEGO, Dec. ... At a median ...

Darzalex (Daratumumab) | International Myeloma Foundation

Darzalex (daratumumab) is a highly effective drug used to treat multiple myeloma. Read about who is a candidate, side effects, special warnings.

EMA recommends a new indication for daratumumab in adult ...

as monotherapy for patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and ...

Daratumumab and its potential in the treatment of multiple myeloma

Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against unique CD38 epitope with broad-spectrum killing activity.

FDA Expands Darzalex Faspro Indication in Myeloma - Medscape

Daratumumab and hyaluronidase-fihj, which was first approved in 2020, has a range of other indications in multiple myeloma. Sharon Worcester, MA ...

Indications & Dosing - darzalex faspro

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: In combination with bortezomib, ...

Official Consumer Website | DARZALEX® & DARZALEX FASPRO ...

DARZALEX FASPRO® is a prescription medicine used to treat adult patients with multiple myeloma: in combination with the medicines bortezomib, lenalidomide, and ...

FDA approves daratumumab and hyaluronidase-fihj for multiple ...

for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous dosing of daratumumab.

Clinical Trials Using Daratumumab and Hyaluronidase-fihj - NCI

Iberdomide may be able to suppress multiple myeloma by directly killing cancer cells and also by stimulating the immune system. Daratumumab is a monoclonal ...

Addition of daratumumab to multiple myeloma backbone regimens ...

Daratumumab is a CD38-targeted human IgG monoclonal antibody that exerts its antineoplastic effect through complement-dependent cytotoxicity, ...

the GRIFFIN trial | Blood | American Society of Hematology

Recommended frontline treatment of transplant-eligible newly diagnosed multiple myeloma (MM; NDMM) includes induction therapy, high-dose ...